Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Sleep and circadian disorders in Alzheimer's disease (AD) are more frequent than in the general population and appear early in the course of the disease. Quality of sleep and quality of life are parallel in these patients, and such disorders also represent a heavy burden for caregivers. Although alterations in melatonin and hypocretins (orexins) seem to play a key role in the origin of these disturbances, the etiology of these disorders is multifactorial, including many factors such as environment, behavior, treatments, and comorbidities, among others. A comprehensive evaluation of sleep in each patient is essential in the design of the treatment that includes nonpharmacological and pharmacological approaches. One particularly interesting point is the possibility of a role of sleep disorders in the pathogenesis of AD, raising the possibility that treating the sleep disorder may alter the course of the disease. In this review, we present an update on the role of sleep disorders in AD, the bidirectional influence of sleep problems and AD, and treatment options. Behavioral measures, bright light therapy (BLT), melatonin, and other drugs are likely well known and correctly managed by the physicians in charge of these patients. In spite of the multiple treatments used, evidence of efficacy is scarce and more randomized double-blind placebo-controlled studies are needed. Future directions for treatment are the establishment of BLT protocols and the development of drugs with new mechanisms of action, especially hypocretin receptor antagonists, melatonin receptor agonists, and molecules that modulate the circadian clock.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878 · cited 1×
“Hypocretin-1 and -2 are produced by a small cluster of neurons in the posterior hypothalamus.(51,52) The”
Neurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466 · cited 1×
“Hypocretin-1 and -2 are produced by a small cluster of neurons in the posterior hypothalamus.(51,52) The”
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., Fujiki, N., Nishino, S., & Holtzman, D. M. (2009) · Science · doi:10.1126/science.1180962 · Cited by 1,565
Yaffe, K., Laffan, A. M., Harrison, S. L., Redline, S., Spira, A. P., Ensrud, K. E., Ancoli-Israel, S., & Stone, K. L. (2011) · JAMA · doi:10.1001/jama.2011.1115 · Cited by 1,137 · cited 2×
“35 However, Yaffe et al 36 found that the oxygen desaturation index and the percentage of time in apnea or hypopnea were associated with cognitive decline but not with sleep fragmentation or sleep duration.”
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996 · cited 1×
“Some authors have even suggested a possible preventive effect for the progression of the AD.(10,41,50,72) As mentioned in the previous section, a thorough evaluation, including habits, comorbidities, and treatments, is critical to choosing the most appropriate treatment for each patient.”
Riemersma-van der Lek, R. F. (2008) · JAMA · doi:10.1001/jama.299.22.2642 · Cited by 803 · cited 5×
“104 The season could have an effect on the response to BLT. Burns et al, 105 applying bright light at 1,000 lux from 10 am to 12 noon, found that the benefit was higher during winter than during summer.”
InfluentialLim, A. S. P., Kowgier, M., Yu, L., Buchman, A. S., & Bennett, D. A. (2013) · Sleep · doi:10.5665/sleep.2802 · Cited by 793 · cited 1×
“Some authors have even suggested a possible preventive effect for the progression of the AD.(10,41,50,72) As mentioned in the previous section, a thorough evaluation, including habits, comorbidities, and treatments, is critical to choosing the most appropriate treatment for each patient.”
Sleep Quality and Preclinical Alzheimer Disease
Ju, Y.-E. S., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P., Morris, J. C., & Holtzman, D. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2334 · Cited by 744 · cited 1×
“45 The physiopathological mechanism is not completely understood, but an association between sleep disturbances and amyloid-β accumulation has been demonstrated in mice 10,11,40 and humans.”
Self-reported sleep and β-amyloid deposition in community-dwelling older adults
Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., Zhou, Y., Wong, D. F., Ferrucci, L., & Resnick, S. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4258 · Cited by 570
Born, J., Rasch, B., & Gais, S. (2006) · The Neuroscientist · doi:10.1177/1073858406292647 · Cited by 557
Amnestic MCI or prodromal Alzheimer's disease?
Dubois, B., & Albert, M. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00710-0 · Cited by 543
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“However, the risk of undesirable side effects is also high.(137) Trazodone is a triazolopyridine antidepressant that offers a dual action on serotonergic receptors by blocking the 2A receptor and inhibiting serotonin reuptake.”
Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease
Musiek, E. S., Xiong, D. D., & Holtzman, D. M. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.121 · Cited by 529 · cited 1×
“On the other hand, AD also influences sleep, especially the sleep–wake cycle.(49) Patients with AD suffer some disturbances in the secretion of neurotransmitters related to sleep– wake systems, mainly hypocretins (orexins) and melatonin secretion.”
Tranah, G. J., Blackwell, T., Stone, K. L., Ancoli‐Israel, S., Paudel, M. L., Ensrud, K. E., Cauley, J. A., Redline, S., Hillier, T. A., Cummings, S. R., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22468 · Cited by 525
Nonpharmacologic Management of Behavioral Symptoms in Dementia
Gitlin, L. N., Kales, H. C., & Lyketsos, C. G. (2012) · JAMA · doi:10.1001/jama.2012.36918 · Cited by 495
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions
Ripley, B., Overeem, S., Fujiki, N., Nevsimalova, S., Uchino, M., Yesavage, J., Di Monte, D., Dohi, K., Melberg, A., Lammers, G. J., et al. (2001) · Neurology · doi:10.1212/wnl.57.12.2253 · Cited by 415
A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., & Thal, L. J. (2003) · Sleep · doi:10.1093/sleep/26.7.893 · Cited by 407
Neurocognitive Impairment in Obstructive Sleep Apnea
Lal, C., Strange, C., & Bachman, D. (2012) · Chest · doi:10.1378/chest.11-2214 · Cited by 406
Guarnieri, B., Adorni, F., Musicco, M., Appollonio, I., Bonanni, E., Caffarra, P., Caltagirone, C., Cerroni, G., Concari, L., Cosentino, F. I. I., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335363 · Cited by 393
Ancoli-Israel, S., Gehrman, P., Martin, J. L., Shochat, T., Marler, M., Corey-Bloom, J., & Levi, L. (2003) · Behavioral Sleep Medicine · doi:10.1207/s15402010bsm0101_4 · Cited by 347 · cited 1×
“93 101 Ancoli-Israel et al 102 compared bright light during morning versus dim light during morning and bright light during evening for 10 days.”
Sleep disturbance in mild to moderate Alzheimer’s disease
MORAN, M., LYNCH, C., WALSH, C., COEN, R., COAKLEY, D., & LAWLOR, B. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2004.12.005 · Cited by 346
A Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia
Mendelson, W. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0409 · Cited by 308
Liu, R.-Y., Zhou, J.-N., van Heerikhuize, J., Hofman, M. A., & Swaab, D. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5394 · Cited by 304
Figueiro, M., Plitnick, B., Lok, A., Jones, G., Higgins, P., Hornick, T., & Rea, M. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s68557 · Cited by 211
Forbes, D., Blake, C. M., Thiessen, E. J., Peacock, S., & Hawranik, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003946.pub4 · Cited by 194 · cited 1×
“In spite of these positive reports, the Cochrane systematic review carried out by Forbes et al 108 concluded that there is insufficient evidence of its effectiveness.”
Is there a link between sleep changes and memory in Alzheimer's disease?
Rauchs, G., Schabus, M., Parapatics, S., Bertran, F., Clochon, P., Hot, P., Denise, P., Desgranges, B., Eustache, F., Gruber, G., et al. (2008) · NeuroReport · doi:10.1097/wnr.0b013e32830867c4 · Cited by 179 · cited 1×
“For example, Rauchs et al 19,20 found that the mean intensity of fast spindles was positively correlated, in AD patients, with immediate recall performance, while the amount of SWS was positively correlated with the ability to retrieve recent autobiographical memories.”
Bright light therapy for agitation in dementia: a randomized controlled trial
Burns, A., Allen, H., Tomenson, B., Duignan, D., & Byrne, J. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209008886 · Cited by 171 · cited 2×
“They found only ten studies that fulfilled their search criteria 93,101–105,109–”
Camargos, E. F., Louzada, L. L., Quintas, J. L., Naves, J. O. S., Louzada, F. M., & Nóbrega, O. T. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.174 · Cited by 170 · cited 1×
“In a double-blind, randomized, controlled trial in 30 patients with AD, trazodone (50 mg during 2 weeks) increased total nocturnal sleep time without significant daytime somnolence or negative effects on cognition or functionality.(139) There were no serious adverse effects.”
Possible therapeutic value of melatonin in mild cognitive impairment: A retrospective study
Furio, A. M., Brusco, L. I., & Cardinali, D. P. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00491.x · Cited by 167 · cited 1×
“124 In a retrospective analysis of 25 MCI patients, Furio et al 125 found that melatonin significantly improved cognitive and emotional performance and daily sleep–wake cycles.”
Yamadera, H., Ito, T., Suzuki, H., Asayama, K., Ito, R., & Endo, S. (2000) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2000.00711.x · Cited by 148
Light therapy and Alzheimer’s disease and related dementia: Past, present, and future
Hanford, N., & Figueiro, M. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121645 · Cited by 136
Light Treatment for Neuropsychiatric Behaviors in Alzheimer's Disease
Dowling, G. A., Graf, C. L., Hubbard, E. M., & Luxenberg, J. S. (2007) · Western Journal of Nursing Research · doi:10.1177/0193945907303083 · Cited by 121
Altered CSF Orexin and α-Synuclein Levels in Dementia Patients
Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111655 · Cited by 104
Shih, H.-I., Lin, C.-C., Tu, Y.-F., Chang, C.-M., Hsu, H.-C., Chi, C.-H., & Kao, C.-H. (2015) · Medicine · doi:10.1097/md.0000000000000809 · Cited by 55
“Sundowning” as a biological phenomenon: current understandings and future directions: an update
Gnanasekaran, G. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0431-3 · Cited by 38 · cited 1×
“22 25 This phenomenon corresponds to an exacerbation of behavioral symptoms of dementia in the late afternoon.”
Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
Song, H. R., Woo, Y. S., Wang, H.-R., Jun, T.-Y., & Bahk, W.-M. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328364f58d · Cited by 22
Cited by
Sleep Disturbance, Cognitive Decline, and Dementia: A Review
Wu, M., Rosenberg, P., Spira, A., & Wennberg, A. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1604351 · Cited by 309
Circadian disruption and sleep disorders in neurodegeneration
Shen, Y., Lv, Q.-K., Xie, W.-Y., Gong, S.-Y., Zhuang, S., Liu, J.-Y., Mao, C.-J., & Liu, C.-F. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00340-6 · Cited by 171
“There is evidence showing a reduction of melatonin level in the prodromal and progressive stages of AD [102].”
BackgroundThe discovery of suvorexant, the first orexin receptor drug for insomnia
Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J., & Renger, J. J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104837 · Cited by 128
Ahnaou, A., Moechars, D., Raeymaekers, L., Biermans, R., Manyakov, N. V., Bottelbergs, A., Wintmolders, C., Van Kolen, K., Van De Casteele, T., Kemp, J. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13839-6 · Cited by 98
“hippocampus (HPC) CA1-CA3 networks; (2) phase-amplitude cross frequency coupling (PAC) between”
BackgroundA review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Metadata
- Authors
- Urrestarazu, E., & Iriarte, J.
- Venue
- Nature and Science of Sleep
- Publisher
- Informa UK Limited
- Published
- 2016-01
- Volume
- 8
- Pages
- 21
- ISSN
- 1179-1608 (ISSN-L)
- OpenAlex
- W2233936068
- Cited by
- 117
- References
- 37
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.